SAGE Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

SAGE 63.50 +0.58 (0.92%)
price chart
Sage Therapeutics, Inc. (SAGE) Given Buy Rating at Royal Bank Of Canada
Sage Therapeutics, Inc. logo Royal Bank Of Canada reaffirmed their buy rating on shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) in a research note issued to investors on Wednesday morning. Royal Bank Of Canada currently has a $117.00 target price ...
Sage Therapeutics Is Developing These Key Products  Market Realist
Sage Therapeutics Could Still Become A Leader In Neurology  Benzinga
Implied Volatility Surging for Sage Therapeutics, Inc. (SAGE) Stock Options
Clearly, options traders are pricing in a big move for Sage Therapeutics, but what is the fundamental picture for the company? Currently, Sage Therapeutics is a Zacks Rank #3 (Hold) in the Medical - Drugsindustry that ranks in the Top 36% of our Zacks ...
Dynamic Technology Lab Private Ltd Boosts Position in Sage Therapeutics, Inc ...
Sage Therapeutics logo Dynamic Technology Lab Private Ltd increased its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 164.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission.
Royal Bank Of Canada Reaffirms Buy Rating for Sage Therapeutics, Inc. (SAGE)  TrueBlueTribune
Sage Therapeutics (SAGE) & Its Rivals Head-To-Head Comparison  Dispatch Tribunal
Analyst Stance On Two Stocks: Invesco Ltd. (IVZ), Sage Therapeutics, Inc. (SAGE)
The recently concluded session had traders exchanging Invesco Ltd. (NYSE:IVZ) high level. Roughly 2.77 million shares changed hands compared to the three-month volume average 2.44 million shares.
Sage Therapeutics Inc Risk Points versus Health Care
This is a scatter plot analysis of the critical risk points from the option market for Sage Therapeutics Inc (NASDAQ:SAGE) compared to its own past and the Health Care ETF.
Hot On The Charts: KalVista Pharmaceuticals, Inc. (KALV), Sage Therapeutics ...
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) traded at an unexpectedly high level on 11/10/2017 when the stock experienced a -1.86% loss to a closing price of $10.
Delving into Shares of Sage Therapeutics, Inc. (NasdaqGM:SAGE): Quant Update
At the time of writing, Sage Therapeutics, Inc. (NasdaqGM:SAGE) has a Piotroski F-Score of 1. The F-Score may help discover companies with strengthening balance sheets.
Currently Undervalued Or Overvalued? – Sage Therapeutics, Inc. (SAGE), VIVUS ...
Sage Therapeutics, Inc. (NASDAQ:SAGE) attracted a lower number of shares in volume with 0.4 million contracts traded on 17-Oct-17.
Analysts See $-1.91 EPS for SAGE Therapeutics (SAGE); Phi (PHII) Has 0.68 ...
Sage Therapeutics, Inc. (SAGE) Stock Rating Reaffirmed by Goldman Sachs ...  StockNewsTimes
An End-of-Day Technical Review: Sage Therapeutics, Inc. (SAGE), Petroleo ...
Wall Street is only getting more bullish on the stock, with 13 of analysts who cover SAGE having a buy-equivalent rating. Analysts have placed a $86.07 price target on Sage Therapeutics, Inc., suggesting a 38.69% gain from recent close. It's currently ...
An Inside Look at the Technicals For Sage Therapeutics, Inc. (NasdaqGM:SAGE)
Sage Therapeutics, Inc. (NasdaqGM:SAGE) currently has a current ratio of 9.02. The current ratio, which is also known as the working capital ratio, is a liquidity ratio that displays the proportion of current assets of a business relative to the ...